David Heller

David Heller

Auto-generated profile, based on publicly available information

David Heller

Department of Surgery, Schulze Diabetes Institute, University of Minnesota Medical Center, Minneapolis, Minnesota, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
ASAmar Singh
Amar Singh
SRSabarinathan Ramachandran
Sabarinathan Ramachandran
Melanie L. GrahamMelanie L. Graham
Melanie L. Graham
SDSaeed Daneshmandi
Saeed Daneshmandi
DHDavid Heller
David Heller
BHBernhard J. Hering
Bernhard J. Hering
Immune tolerance to allografts has been pursued for decades as an important goal in transplantation. Administration of apoptotic donor splenocytes effectively induces antigen-specific tolerance to allografts in murine studies. Here we show that two peritransplant infusions of apoptotic donor leukocytes under short-term immunotherapy with antagonistic anti-CD40 antibody 2C10R4, rapamycin, soluble tumor necrosis factor receptor and anti-interleukin 6 receptor antibody induce long-term (≥1 year) tolerance to islet allografts in 5 of 5 nonsensitized, MHC class I-disparate, and one MHC class II DRB allele-matched rhesus macaques. Tolerance in our preclinical model is associated with a regulatory network, involving antigen-specific Tr1 cells exhibiting a distinct transcriptome and indirect specificity for matched MHC class II and mismatched class I peptides. Apoptotic donor leukocyte infusions warrant continued investigation as a cellular, nonchimeric and translatable method for inducing antigen-specific tolerance in transplantation.

26 October 2021 in Gut
Verified
Journal Article
Open access
PDF file
BLBomi Lee
Bomi Lee
HNHong Namkoong
Hong Namkoong
YYYan Yang
Yan Yang
HHHuang Huang
Huang Huang
DHDavid Heller
David Heller
AHAida Habtezion
Aida Habtezion
Objective: Chronic pancreatitis (CP) is a potentially fatal disease of the exocrine pancreas, with no specific or effective approved therapies. Due to difficulty in accessing pancreas tissues, little is known about local immune responses or pathogenesis in human CP. We sought to characterise pancreatic immune responses using tissues derived from patients with different aetiologies of CP and non-CP organ donors in order to identify key signalling molecules associated with human CP. Design: We performed single-cell level cellular indexing of transcriptomes and epitopes by sequencing and T-cell receptor (TCR) sequencing of pancreatic immune cells isolated from organ donors, hereditary and idiopathic patients with CP who underwent total pancreatectomy. We validated gene expression data by performing flow cytometry and functional assays in a second patient with CP cohort. Results: Deep single-cell sequencing revealed distinct immune characteristics and significantly enriched CCR6+ CD4+ T cells in hereditary compared with idiopathic CP. In hereditary CP, a reduction in T-cell clonality was observed due to the increased CD4+ T (Th) cells that replaced tissue-resident CD8+ T cells. Shared TCR clonotype analysis among T-cell lineages also unveiled unique interactions between CCR6+ Th and Th1 subsets, and TCR clustering analysis showed unique common antigen binding motifs in hereditary CP. In addition, we observed a significant upregulation of the CCR6 ligand (CCL20) expression among monocytes in hereditary CP as compared with those in idiopathic CP. The functional significance of CCR6 expression in CD4+ T cells was confirmed by flow cytometry and chemotaxis assay. Conclusion: Single-cell sequencing with pancreatic immune cells in human CP highlights pancreas-specific immune crosstalk through the CCR6-CCL20 axis, a signalling pathway that might be leveraged as a potential future target in human hereditary CP.

12 June 2020 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
YNYoshihide Nanno
Yoshihide Nanno
JWJoshua J. Wilhelm
Joshua J. Wilhelm
DHDavid Heller
David Heller
RSRobben Schat
Robben Schat
MFMartin L. Freeman
Martin L. Freeman
MBMelena D. Bellin
Melena D. Bellin

9 October 2017 in Journal of Diabetes
Verified
Journal Article
Closed access
PDF file
MKMuhammed Kizilgul
Muhammed Kizilgul
JWJoshua J. Wilhelm
Joshua J. Wilhelm
GBGregory J. Beilman
Gregory J. Beilman
SCSrinath Chinnakotla
Srinath Chinnakotla
TDTy B. Dunn
Ty B. Dunn
MBMelena D. Bellin
Melena D. Bellin

6 April 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
BLBomi Lee
Bomi Lee
HNHong Namkoong
Hong Namkoong
YYYan Yang
Yan Yang
HHHuang Huang
Huang Huang
DHDavid Heller
David Heller
AHAida Habtezion
Aida Habtezion
Objective: Chronic pancreatitis (CP) is a potentially fatal disease of the exocrine pancreas, with no specific or effective approved therapies. Due to difficulty in accessing pancreas tissues, little is known about local immune responses or pathogenesis in human CP. We sought to characterize pancreas immune responses using tissues derived from patients with different etiologies of CP and non-CP organ donors in order to identify key signaling molecules associated with human CP. Design: We performed single-cell level cellular indexing of transcriptomes and epitopes by sequencing (CITE-Seq) and T cell receptor sequencing of pancreatic immune cells isolated from organ donors, hereditary, and idiopathic CP patients who underwent total pancreatectomy. We validated gene expression data by performing flow cytometry and functional assay in the second CP patient cohort. Results: Deep single-cell sequencing revealed distinct immune characteristics and significantly enriched CCR6 + CD4 + T cells in hereditary compared with idiopathic CP. In hereditary CP, a reduction in T cell clonality was observed due to the increased CD4 + T (Th) cells that replaced tissue-resident CD8 + T cells. Shared TCR clonotype analysis among T cell lineages also unveiled unique interactions between CCR6 + Th and Th1 subsets, and TCR clustering analysis showed unique common antigen binding motifs in hereditary CP. In addition, we observed a significant upregulation of the CCR6 ligand ( CCL20 ) among monocytes in hereditary CP as compared with those in idiopathic CP. The functional significance of CCR6 expression in CD4 + T cells was confirmed by flow cytometry and chemotaxis assay. Conclusion: Single-cell sequencing with pancreatic immune cells in human CP highlights pancreas-specific immune crosstalk through the CCR6-CCL20 axis that might be leveraged as a potential future target in human hereditary CP. Significance of this study: What is already known about this subject?: Chronic pancreatitis (CP) is considered an irreversible fibroinflammatory pancreatic disease and remains a major source of morbidity among gastrointestinal diseases with no active approved therapy. Inflammation is a known hallmark and contributor to CP pathogenesis. However, little is known about local immune responses in human CP especially with different etiologies. What are the new findings?: Single-cell RNA sequencing of pancreatic immune cells from CP patients and organ donors revealed distinct immune transcriptomic features in CP versus non-diseased controls and hereditary versus idiopathic CP. Single-cell T cell receptor sequencing unveiled pancreas-specific clonal expansion in CD8 + T cells and CD4 + T cells-driven unique TCR repertoire changes in hereditary CP. We identified that the CCR6-CCL20 axis was significantly upregulated in hereditary CP compared with controls or idiopathic CP suggesting a potential future target for human hereditary CP. How might it impact on clinical practice in the foreseeable future?: The results of this study will improve our understanding of CP heterogeneity and identify distinct immune responses in different types of human CP that could provide novel conceptual directions for therapeutic strategies in treating hereditary and idiopathic CP. The CCR6-CCL20 axis found in hereditary CP could be a potential novel targetable signaling pathways in the treatment of hereditary CP.